Summary

Recent clinical results from the AMDS PERSEVERE trial have shattered industry expectations. The data revealed that patients with acute DeBakey Type I dissections who received the AMDS Hybrid Prosthesis experienced a significant reduction in complications, proving that the hybrid approach offers a robust alternative to traditional options. This breakthrough solidified confidence in the technology's safety and efficacy for high-risk thoracic cases. Meanwhile, the FDA recently approved Artivion's humanitarian device exemption for this AMDS hybrid, confirming the drug's unique safety profile suitable for emergency surgery. These developments mark a crucial turning point in the management of severe thoracic injuries today.

Title

Homepage - Artivion

Description

Our purpose is to develop simple, elegant solutions that address cardiac and vascular surgeons’ most difficult challenges in treating patients with diseases of the aorta and to deliver breakthrough technologies of unsurpassed quality that have far-reachin

Keywords

amds, adhesive, syringe, stent, system, there, patient, versions, graft, data, heart, valve, hybrid, trial, prosthesis, acute, type

NS Lookup

A 35.199.179.76

Dates

Created 2026-04-12

Updated 2026-04-30

Summarized 2026-05-01